Abortive Seizure Agent Staccato Alprazolam Meets Primary End Point in Phase 2

Engage touts long-awaited positive data for its inhaler for seizures
March 12, 2020
Engage Therapeutics Announces Phase 2b StATES Study of Staccato® Alprazolam for Seizure Cessation Meets Primary Endpoint
March 12, 2020

The Engage Therapeutics product met its primary end point in the StATES study, with an onset of action for ceasing seizure activity of approximately 30 seconds, on average.

Engage Therapeutics has announced that its investigational abortive seizure treatment Staccato alprazolam has met its primary end point in the phase 2 StATES study (NCT03478982), with a meaningful proportion of responders achieving cessation of seizure activity within 2 minutes of administration without recurrence within a 2-hour window…

To continue reading the article, click here to visit Neurology Live